Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib
Max J. Gordon(Oregon Health & Science University), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Jonathon B. Cohen(Emory University), Michael C. Churnetski(Emory University), Hamood Alqahtani(University of California San Diego), Stephen M. Amrock(Oregon Health & Science University), Spencer James(Dartmouth–Hitchcock Medical Center), Xavier Rivera(University of Arizona), Adam S. Kittai(The Ohio State University Wexner Medical Center), Daniel O. Persky(University of Arizona), Michael Y. Choi(University of California San Diego), Sheila Hoff(University of California San Diego), Sudhir Manda(Dartmouth–Hitchcock Medical Center), Stephen E. Spurgeon(Howard Hughes Medical Institute)
Cited by 86
Related Papers
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
|The Lancet|2017|2.1k
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|454
Evolution and patterns of global health financing 1995–2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries
|The Lancet|2017|296
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213
Immune Checkpoint Inhibitors in Organ Transplant Patients
|Journal of Immunotherapy|2017|150